• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Levetrim
    / Trima


    Active Ingredient
    Levetiracetam 250 mg, 500 mg, 1,000 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    60 X 250 mg

    partial basket chart 21384 12440

    Film Coated Tablets

    60 X 500 mg

    partial basket chart 21385 12441

    Film Coated Tablets

    60 X 1000 mg

    partial basket chart 21386 12442

    Related information


    Dosage

    See prescribing information for full details.


    Indications

    For adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy.As adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. As monotherapy in the treatment of partial onset seizures with or without secondary generalization in patients from 16 years of age with newly diagnosed epilepsy.
    Treatment of primary generalized tonic-clonic seizures (PGTCS) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.


    Contra-Indications

    Hypersensitivity to levetiracetam or other pyrrolidone derivatives or any of the excipients. Not for use in children under 4 years of age.


    Special Precautions

    Avoid alcohol use during treatment.
    See prescribing information for full details.


    Side Effects

    Drowsiness, weakness, fatigue.
    See prescribing information for full details.


    Drug interactions

    See prescribing information for full details.


    Manufacturer
    Trima Israel Pharmaceutical Products Maabarot Ltd. Israel
    CLOSE